SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-012511
Filing Date
2020-11-04
Accepted
2020-11-04 11:32:24
Documents
61
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20200930x10q.htm 10-Q 780346
2 EX-31.1 anvs-20200930ex311fbf266.htm EX-31.1 12629
3 EX-31.2 anvs-20200930ex3122e98b5.htm EX-31.2 12663
4 EX-32.1 anvs-20200930ex321818541.htm EX-32.1 5744
5 EX-32.2 anvs-20200930ex32239b507.htm EX-32.2 5730
  Complete submission text file 0001558370-20-012511.txt   3772262

Data Files

Seq Description Document Type Size
6 EX-101.INS anvs-20200930.xml EX-101.INS 576957
7 EX-101.SCH anvs-20200930.xsd EX-101.SCH 47940
8 EX-101.CAL anvs-20200930_cal.xml EX-101.CAL 30266
9 EX-101.DEF anvs-20200930_def.xml EX-101.DEF 161878
10 EX-101.LAB anvs-20200930_lab.xml EX-101.LAB 376062
11 EX-101.PRE anvs-20200930_pre.xml EX-101.PRE 277777
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 201285717
SIC: 2834 Pharmaceutical Preparations